Recurrent Adult Brain Tumor
52
1
1
36
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
30 trials with published results (58%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
25.0%
13 terminated out of 52 trials
73.5%
-13.0% vs benchmark
0%
0 trials in Phase 3/4
83%
30 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (52)
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Yoga Therapy in Treating Patients With Malignant Brain Tumors
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma